AI 기반 병리학 시장 : 전략적 인사이트 및 예측(2026-2035년)

The AI-Powered Pathology Market is forecast to grow at a CAGR of 12.7%, reaching USD 589.84 million in 2035 from USD 201.72 million in 2026.

The global AI-powered pathology market is experiencing transformative growth, driven by the rising incidence of cancer and the accelerating digitalization of pathology laboratories. AI-powered pathology combines machine learning, deep learning, computer vision, and digital pathology technologies to assist pathologists in detecting, classifying, quantifying, and interpreting histopathological findings from digitized tissue slides. The market includes software solutions, supporting hardware infrastructure, and implementation services that enhance diagnostic workflows while improving laboratory productivity and diagnostic consistency. Demand is increasing because cancer incidence continues creating sustained demand for pathology services, as histopathological evaluation remains the reference standard for diagnosing many malignancies. Healthcare providers are expanding digital pathology capabilities to accommodate increasing specimen volumes while reducing reporting variability across institutions. This operational pressure increases demand for AI-assisted diagnostic platforms capable of automating repetitive image analysis tasks and prioritizing clinically significant findings. The market depends heavily on advances in whole-slide imaging, computational pathology, cloud computing, and standardized digital workflows. These enabling technologies support large-scale image acquisition, secure data storage, algorithm training, and remote consultation while allowing AI models to operate within existing laboratory infrastructure. Their combined maturity is expanding the practical implementation of AI-assisted pathology across routine clinical practice.

Market Drivers

Increasing Digital Pathology Adoption Across Clinical Laboratories

• Digital pathology provides the technological foundation required for artificial intelligence to operate within routine diagnostic workflows. Hospitals and diagnostic laboratories are increasingly digitizing glass slides because centralized image management enables remote consultations, workflow standardization, and computational analysis. This transition exposes laboratories to substantially larger digital datasets that AI algorithms can process for screening, quantification, and diagnostic decision support. Vendors are integrating AI capabilities directly into digital pathology platforms to reduce implementation complexity and strengthen clinical adoption. The combination of digital slide repositories and AI-assisted analysis establishes a scalable pathology ecosystem that supports long-term laboratory modernization.

Rising Oncology Burden Is Expanding Demand for AI-Assisted Diagnostic Support

• Histopathological examination remains the diagnostic cornerstone for most solid tumors, making pathology capacity directly dependent on cancer incidence. Growing biopsy volumes are increasing diagnostic workloads while healthcare systems continue facing shortages of experienced pathologists in many regions. Laboratories are adopting AI-assisted image analysis to prioritize suspicious regions, automate biomarker quantification, and reduce manual interpretation time without replacing clinical oversight. Technology developers are therefore concentrating product development on oncology applications because these areas generate the highest clinical demand and strongest evidence base. The resulting workflow improvements strengthen diagnostic consistency while supporting precision oncology programs.

Regulatory Progress Is Accelerating Commercial Deployment of Clinical AI Solutions

• Clinical adoption depends on regulatory confidence because pathology software directly influences diagnostic decision-making. Regulatory agencies are expanding frameworks for software as a medical device (SaMD), encouraging developers to generate robust clinical validation and post-market evidence. Manufacturers are investing more heavily in multicenter validation studies because regulatory clearance increases physician confidence and procurement opportunities. Healthcare providers consequently view regulatory-approved AI applications as lower-risk investments compared with research-only solutions. This regulatory evolution strengthens commercial deployment across routine pathology laboratories.

Precision Medicine Is Increasing Demand for Quantitative Biomarker Assessment

• Precision oncology relies on accurate biomarker interpretation to guide targeted therapies and immunotherapy selection. Manual biomarker scoring often introduces inter-observer variability, particularly for complex immunohistochemistry assessments. Healthcare providers are implementing AI-assisted quantification to improve reproducibility and support standardized treatment decisions. Technology companies are expanding algorithms for companion diagnostic workflows because pharmaceutical developers increasingly require consistent biomarker evaluation during clinical development. These capabilities position AI-powered pathology as an important component of personalized medicine.

Market Restraints

• High implementation costs associated with whole-slide imaging systems, storage infrastructure, software validation, and laboratory integration continue limiting adoption among resource-constrained healthcare providers. Regulatory compliance requirements, cybersecurity expectations, and continuous algorithm validation increase commercialization complexity while extending product development timelines. Limited availability of standardized, diverse, and annotated pathology datasets constrains algorithm generalizability across different populations, tissue preparation methods, and laboratory environments.

Technology and Segment Insights

By Component

• Software represents the largest source of innovation because artificial intelligence algorithms, workflow orchestration platforms, image management systems, and decision-support applications generate the primary clinical value. Healthcare organizations are increasingly prioritizing enterprise software platforms that integrate seamlessly with laboratory information systems and whole-slide imaging infrastructure. This requirement increases demand for interoperable solutions capable of supporting routine diagnostics rather than isolated analytical tasks. Vendors are continuously enhancing algorithm performance, cloud deployment, cybersecurity, and workflow automation to improve scalability across large pathology networks.

By Clinical Application

• Oncology constitutes the leading clinical application because histopathological evaluation remains essential for cancer diagnosis, grading, staging, biomarker assessment, and treatment planning. Cancer screening programs and precision medicine initiatives are continuously increasing tissue specimen volumes processed by pathology laboratories. Healthcare providers are adopting AI-assisted pathology to improve diagnostic consistency, automate biomarker quantification, and reduce reporting turnaround times. Technology developers are concentrating product pipelines on breast, prostate, lung, colorectal, and other common cancers because these indications present substantial clinical evidence and commercial opportunity.

By End User

• Hospitals represent the largest end-user segment because comprehensive pathology laboratories support a broad range of surgical pathology, oncology, and multidisciplinary diagnostic services. Healthcare systems are expanding digital pathology infrastructure to improve laboratory productivity while facilitating collaboration across multiple clinical departments. AI-powered decision support increasingly assists hospital pathologists in prioritizing complex cases, standardizing interpretations, and managing rising diagnostic workloads. Independent diagnostic laboratories and academic and research institutes represent additional significant end-user segments.

Competitive and Strategic Outlook

• The competitive landscape features specialized AI pathology companies and larger diagnostic organizations. F. Hoffmann-La Roche Ltd. remains strategically distinct because it combines global diagnostics leadership with an integrated digital pathology ecosystem supporting precision oncology and companion diagnostics. PathAI, Inc. differentiates itself through its strong focus on AI for pathology, translational medicine, and pharmaceutical research. Paige AI, Inc. distinguishes itself through clinically validated AI applications designed specifically for routine pathology diagnostics. Ibex Medical Analytics Ltd. differentiates itself through AI-powered diagnostic decision support for routine pathology workflows. Aiforia Technologies Plc establishes differentiation through a cloud-based AI platform supporting both clinical diagnostics and biomedical research. Proscia Inc. differentiates itself through an enterprise digital pathology platform combining workflow management, image management, and AI within a unified ecosystem.
• Strategic developments include increasing integration of multimodal AI combining histopathology with genomic and clinical data, expansion of companion diagnostics, and growth of cloud-based pathology platforms. Companies are forming partnerships to strengthen algorithm validation, clinical adoption, and regulatory submissions. Technology expansions focus on enterprise software platforms, workflow automation, and biomarker quantification. Companies that successfully combine validated algorithms with scalable digital pathology ecosystems are expected to lead the market.

Conclusion

• The AI-powered pathology market is poised for significant growth, driven by rising cancer diagnostic volumes, digital pathology adoption, and precision medicine. The evolution from algorithm-centric innovation toward enterprise-wide diagnostic transformation is reshaping pathology practice. Companies that successfully deliver clinically validated, interoperable, and scalable AI-powered pathology solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding digital health infrastructure will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. AI-Powered Pathology Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Pathology Industry Overview
• 3.3 Evolution of AI in Pathology
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Digital Pathology Ecosystem Overview
• 3.8 Adoption of AI Across Pathology Workflow
• 3.9 Testing Volume Analysis
• 3.10 Installed Base of Digital Pathology Systems
• 3.11 User Adoption Analysis
• 3.12 Clinical Workflow Integration
• 3.13 AI-Assisted Diagnostic Workflow Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Clinical Validation Studies
• 6.4 AI Algorithm Development Landscape
• 6.5 Digital Pathology Platform Innovation
• 6.6 Pipeline Analysis
• 6.7 AI Integration Across Laboratory Workflows
• 6.8 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. AI-Powered Pathology Market Landscape Analysis

• 8.1 Analysis by Technology
• 8.2 Analysis by Deployment Model
• 8.3 Analysis by Clinical Application
• 8.4 Analysis by End User
• 8.6 Analysis by AI Functionality

9. AI-Powered Pathology Market Segment Analysis (2021-2035)

• 9.1 By Technology
  • 9.1.1 Machine Learning
  • 9.1.2 Deep Learning
  • 9.1.3 Computer Vision
  • 9.1.4 Natural Language Processing
  • 9.1.5 Generative AI
  • 9.1.6 Others
• 9.2 By Component
  • 9.2.1 Software
  • 9.2.2 Hardware
  • 9.2.3 Services
• 9.3 By Deployment Model
  • 9.3.1 Cloud-Based
  • 9.3.2 On-Premises
• 9.4 By Clinical Application
  • 9.4.1 Oncology
  • 9.4.2 Gastrointestinal Pathology
  • 9.4.3 Genitourinary Pathology
  • 9.4.4 Dermatopathology
  • 9.4.5 Hematopathology
  • 9.4.6 Pulmonary Pathology
  • 9.4.7 Other Clinical Applications
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Independent Diagnostic Laboratories
  • 9.5.3 Academic & Research Institutes
  • 9.5.4 Others

10. AI-Powered Pathology Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. AI-Powered Pathology Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Japan
• 11.10 China
• 11.11 India
• 11.12 South Korea
• 11.13 Australia
• 11.14 Brazil
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Visiopharm A/S
• 13.3 Tribun Health SAS
• 13.4 Lumea Inc.
• 13.5 Mindpeak GmbH
• 13.6 PathAI, Inc.
• 13.7 Paige AI, Inc.
• 13.8 Ibex Medical Analytics Ltd.
• 13.9 Aiforia Technologies Plc
• 13.10 Proscia Inc.

14. AI-Powered Pathology Market Commercial Forecast Analysis

• 14.1 AI Image Analysis Software
• 14.2 Digital Pathology Workflow Platforms
• 14.3 AI Decision Support Solutions
• 14.4 Computational Pathology Software
• 14.5 Whole Slide Image Management Platforms
• 14.6 AI-Based Biomarker Analysis Solutions

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends